Regulus Therapeutics Inc. buy Wells Fargo & Company
Start price
27.03.25
/
50%
€1.49
Target price
27.03.26
€5.57
Performance (%)
373.15%
Price
07.07.25
€7.05
Summary
This prediction is currently active. With a performance of 373.15% the BUY prediction by Wells_Fargo___Compan is a big success. This prediction currently runs until 27.03.26. The prediction end date can be changed by Wells_Fargo___Compan at any time. Wells_Fargo___Compan has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Regulus Therapeutics Inc. | - | - |
| iShares Core DAX® | 0.734% | 1.458% |
| iShares Nasdaq 100 | -2.686% | -0.146% |
| iShares Nikkei 225® | -2.261% | -2.729% |
| iShares S&P 500 | -1.346% | 0.467% |
Comments by Wells_Fargo___Compan for this prediction
In the thread Regulus Therapeutics Inc. diskutieren
Regulus Therapeutics Inc. (NASDAQ: RGLS) was upgraded by analysts at Wells Fargo & Company from an "equal weight" rating to an "overweight" rating. They now have a $6.00 price target on the stock, up previously from $3.00.
Ratings data for RGLS provided by MarketBeat